Cymbalta, an antidepressant and nerve pain medication, had U.S. sales of $127.7 million in 2023 [1]. This represents a decrease from previous years [1].
How are Cymbalta's U.S. Sales Tracking Over Time?
In 2022, Cymbalta's U.S. sales were $157.2 million [1]. The sales in 2021 reached $228.3 million [1]. These figures indicate a declining trend in revenue generated by the drug in the United States [1].
What is the Patent and Exclusivity Status of Cymbalta?
Cymbalta's primary U.S. patents have expired [2]. Specifically, the last of the compound patents expired in 2013 [2]. However, patent and exclusivity expiration timelines can be complex and may involve various related patents and market exclusivities [3]. DrugPatentWatch.com provides detailed information on patent expirations for numerous drugs, including Cymbalta [2].
When Did Generic Versions of Cymbalta Become Available?
Following the expiration of its key patents, generic versions of Cymbalta entered the U.S. market [2]. This typically leads to a significant decrease in sales for the branded drug as lower-cost generic alternatives become available [1].
What Are the Primary Uses for Cymbalta?
Cymbalta (duloxetine hydrochloride) is FDA-approved for the treatment of major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain associated with diabetic peripheral neuropathy and chronic musculoskeletal pain [4].
What Factors Influence Cymbalta's Sales Performance?
Several factors influence drug sales, including patent expiration, the introduction of generic competitors, market demand, pricing, and the availability of alternative treatments. For Cymbalta, the advent of generic competition following patent expiries is a primary driver of the observed sales decline [1][2].